Navigation Links
Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
Date:5/10/2013

SAN DIEGO, May 10, 2013 /PRNewswire-USNewswire/ -- The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.  This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.

The partnership will integrate Denovo's pharmacogenomic technology into the analysis of biological samples obtained from expanded access programs (EAP's) that ALS-ETF sponsors.  By identifying genomic biomarkers that correlate with patients' responsiveness to treatment, the partners seek to identify appropriate patient subsets for the conduct of subsequent trials. 

"This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians," said Jess Rabourn , Managing Director of ALS-ETF.  Dr. Wen Luo , Chief Scientific Officer for Denovo Biomarkers, noted, "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."

About The ALS Emergency Treatment Fund (ALS-ETF)

The ALS Emergency Treatment Fund, headquartered in San Francisco, is a nonprofit company created to provide near-term treatment options to sufferers of amyotrophic lateral sclerosis (ALS), a fatal disease that compromises patients' ability to move, speak, swallow and breathe.  ALS-ETF, under license from participating pharmaceutical companies, and as authorized by FDA, implements Expanded Access treatment programs (EAP's) for investigational products in development for ALS. ALS-ETF will also leverage data obtained via EAP's to add scientific value to the clinical development of each compound. By observing a broader spectrum of patients than those typically in registration trials, EAP's may illuminate how subgroups of ALS patients respond to treatment, at different stages of disease progression.  Visit www.alsetf.org.

About Denovo Biomarkers

Denovo Biomarkers, based in San Diego, is a privately-held biotechnology company providing novel biomarker approaches to personalized drug development. The company offers the industry's first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology is especially useful for compounds with suboptimal aggregate but heterogeneous late-stage trial results.  By identifying biomarkers correlated with patients' response to drug candidates retrospectively, Denovo enables biopharmaceutical manufacturers to design follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. Visit www.denovobiomarkers.com.

Contact: 
Jess Rabourn , The ALS Emergency Treatment Fund, jess.rabourn@alsetf.org, (415) 637-4774 
Michael Haller , Denovo Biomarkers, mhaller@denovobiomarkers.com, (858) 876-4012

 


'/>"/>
SOURCE The ALS Emergency Treatment Fund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
2. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
3. Bayer Partnership Delivers Industry-First Dose Management Offering
4. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
5. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
6. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
7. Scotland-based Innova Partnerships Ltd. Opens Boston Office
8. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
9. Partnership Aims to Prevent Students from Misusing Prescription Drugs
10. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
11. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
(Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
Breaking Medicine Technology:
(Date:2/5/2016)... Miami, FL (PRWEB) , ... February 05, 2016 ... ... of the largest domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th ... and awareness for kids and adults with muscular dystrophy, ALS and related diseases ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , ... Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated ... hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... in gym use and find themselves having to wait longer to access the treadmills. ... on their New Year’s resolutions to lose weight and get in shape by joining ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... ranked #3 in the 2015 Best in KLAS: Software & Services for HIT ... annual Best in KLAS report independently ranks vendor performance by healthcare executives, managers ...
Breaking Medicine News(10 mins):